Clinical trials: Cholera, open to volunteers
Cholera, Methodology Study
Cholera Control by Case-area Targeted Interventions (CATIs)
To evaluate the effectiveness of the CATI approach among household contacts in the reduction of cumulative incidence of cholera and explore the genome analysis and immune response of V.
- Trial name
- NCT07685574
- Testing
- Cholvax
- Where
- Bangladesh
- Volunteers
- 68,400 people, healthy volunteers welcome
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Cholera Vaccination
Extended Dosing Intervals Trial for Oral Cholera Vaccine, Kenya
Background: Despite efforts to control cholera, outbreaks continue to occur in Kenya. Oral cholera vaccines (OCVs) are a critical tool in cholera prevention strategies.
- Trial name
- NCT07487077
- Testing
- Euvichol-S Oral Cholera Vaccine
- Where
- Kenya
- Volunteers
- 1,071 people, healthy volunteers welcome
- Sponsor
- Albert B. Sabin Vaccine Institute
Diarrhea
A Post-marketing Observational Study of Oral Cholera Vaccine
Chinese survey data indicate that the incidence rate of diarrhea in the general population ranges from 0.17 to 0.70 episodes per person-year, whereas among children under five years of age, the rate is significantly higher…
- Trial name
- NCT07300462
- Testing
- Recombinant subunit B/bacterial cholera vaccine (enteric-coated capsules)
- Where
- 5 sites in China
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Shanghai United Cell Biotechnology Co., Ltd
Shock Hypovolemic, Shock, Septic
Management of Shock in Children With SAM or Severe Underweight and Diarrhea
Diarrhea is one of the leading causes of under-five childhood mortality and accounts for 8% of 5.4 million global under-5 deaths.
- Conditions
- Shock Hypovolemic, Shock, Septic, Blood Transfusion, Adrenaline
- Trial name
- NCT04750070
- Testing
- Blood and Dopamine, Blood and adrenaline
- Where
- Bangladesh
- Volunteers
- 135 people
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Typhoid and/or Cholera Vaccination
CVD 38000: Study of Responses to Vaccination With Typhoid and/or Cholera
This is an open-label, non-randomized study. The purpose of this study is to better understand how vaccines against typhoid fever and cholera affect the normal immune system and bacteria in the intestine.
- Trial name
- NCT03705585
- Testing
- Vivotif Typhoid Oral Vaccine, Vaxchora
- Where
- United States
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Cholera, Water-Related Diseases
Preventative Intervention for Cholera for 7 Days
The first objective of our study is to develop a theory-driven evidence-based targeted water, sanitation, and hygiene (WASH) intervention for household members of diarrhea patients in South Kivu, Democratic Republic of the Congo…
- Conditions
- Cholera, Water-Related Diseases, Diarrhea Infectious
- Trial name
- PICHA-7 (NCT05166850)
- Testing
- PICHA7 mHealth program, Standard Arm
- Where
- 2 sites in Democratic Republic of the Congo
- Volunteers
- 2,900 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Cholera
Vaccine- and Infection-derived Correlates of Protection for Cholera
Background: Vibrio cholerae causes millions of cholera cases and thousands of deaths annually. Vaccines are in short supply. There is no agreement on how to introduce new vaccines or evaluate their effectiveness, and the lack of…
- Trial name
- CoP (NCT06455852)
- Testing
- oral cholera vaccine or typhoid conjugate vaccine
- Where
- Bangladesh
- Volunteers
- 1,221 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Cholera, Diarrhea
Cholera-Hospital-Based-Intervention-for-7-Days (CHoBI7) Water, Sanitation, and Hygiene (WASH) Case Area Targeted Intervention (CATI)
Objective: The investigators objective is to develop and evaluate the effectiveness of a case area targeted water, sanitation, and hygiene (WASH) intervention in reducing cholera infections and increasing sustained WASH behaviors…
- Trial name
- NCT06003816
- Testing
- Cholera-Hospital-Based-Intervention-for-7-Days (CHoBI7) CATI, Standard message
- Where
- 2 sites in Bangladesh
- Volunteers
- 3,140 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Cholera Vaccination Reaction
Phase 1b Ascending Dose Study of PanChol in Healthy Volunteers
Cholera is a serious diarrheal disease that can be fatal within hours of onset. The current available cholera vaccines to prevent the disease are not very effective.
- Trial name
- PanChol (NCT07107516)
- Testing
- PanChol
- Where
- Zambia
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Centre for Infectious Disease Research in Zambia
Bowel Habits, Gut Microbiomes
Study on Changes in Gut Microbiota, Inflammatory Factors, and Bowel Habits Following Oral Administration of Recombinant B-subunit/Whole Cell Cholera Vaccine in a Community Population
This randomized, placebo-controlled clinical trial aims to investigate the effects of oral cholera vaccine administration on three aspects of gut health in healthy adult community members aged 18 years and older: (1) the…
- Conditions
- Bowel Habits, Gut Microbiomes, Inflamatory Markers
- Trial name
- NCT07873346
- Testing
- Receive recombinant B-subunit/whole-cell cholera vaccine
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Zhejiang Provincial Center for Disease Control and Prevention
Cholera
Impact Study of Cholera Vaccination in Endemic Areas - Clinical Surveillance
This project aims to fill this essential knowledge gap by assessing the impact of oral cholera vaccine mass campaigns in 2 sites (urban and rural) in DRC, described in this protocol.
- Trial name
- NCT04853186
- Where
- Democratic Republic of the Congo
- Volunteers
- 6,000 people
- Sponsor
- Epicentre
Cholera Vaccination
Trial to Evaluate Immunogenicity Non-Inferiority, Safety and Lot-to-Lot Consistency of Biovac OCV-S to Euvichol®-Plus
This Phase I/III clinical trial is intended to establish the immunogenicity and safety profile of Biovac OCV-S compared to available WHO pre-qualified vaccine Euvichol®-Plus in healthy adults and children and in adult people…
- Trial name
- NCT07304284
- Testing
- Experimental: Biovac OCV-S (inactivated whole-cell monovalent (O1) oral cholera vaccine), Active Comparator, Euvichol®-Plus
- Where
- 5 sites in South Africa
- Volunteers
- 2,824 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Diarrhea Infectious, Cholera
Testing a Scalable Model of the Cholera Hospital-Based Intervention for 7 Days (CHoBI7)
The findings from previous recent randomized controlled trials of The Cholera Hospital Based Intervention for 7 Days (CHoBI7) demonstrated that this intervention was effective in significantly reducing symptomatic cholera…
- Trial name
- CHoBI7 (NCT06498817)
- Testing
- Standard Recommendation, CHoBI7 Scale-Up Program
- Where
- Bangladesh
- Volunteers
- 1,600 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Cholera Vaccination Reaction
Safety and Immunogenicity Study of the DuoChol Oral Cholera Vaccine in Healthy Participants
The goal of this phase I, open-label, randomized, active-controlled Trial is to evaluate the safety and immunogenicity of the DuoChol Oral Cholera Vaccine in 18 to 45 years old healthy participants in Sweden.
- Trial name
- DuoChol (NCT07270796)
- Testing
- DuoChol, Dukoral®
- Where
- Sweden
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Cholera (Disorder)
Ondansetron to Prevent Oral Rehydration Failure in Children With Cholera
This Phase IIa randomized controlled trial will evaluate whether a single oral dose of ondansetron can reduce oral rehydration failure in children and adolescents with suspected or confirmed cholera and active vomiting.
- Trial name
- NCT07795060
- Testing
- Ondansetron, Standard Cholera Care
- Where
- Republic of the Congo
- Volunteers
- 120 people
- Sponsor
- Public Interest Science Center
Cholera Vaccination
Age-descending Study to Evaluate the Safety and Immunogenicity of the Cholera Conjugate Vaccine in Adults and Children
This phase II study is intended to determine the immunogenicity and safety of single dose and two doses of OSP:rTTHc cholera conjugate vaccine (CCV) with or without alum adjuvant.
- Trial name
- NCT07509047
- Testing
- OSP:rTTHc CCV 25 ㎍ with Aluminum phosphate, OSP:rTTHc CCV 25 ㎍ without Aluminum phosphate, Euvichol®-Plus
- Where
- Kenya
- Volunteers
- 390 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute